Cited by 101Antifungal resistance and susceptibilityFungal Infections and StudiesOcular Infections and Treatments

Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.

Open access
Vazquez, Jose, Reboli, Annette C, Pappas, Peter G, Patterson, Thomas F, Reinhardt, John, Chin-Hong, Peter, Tobin, Ellis, Kett, Daniel H +2 more·2014·BMC Infectious Diseases

Abstract

BACKGROUND: Hospitalized patients are at increased risk for candidemia and invasive candidiasis (C/IC). Improved therapeutic regimens with enhanced clinical and pharmacoeconomic outcomes utilizing existing antifungal agents are still needed. METHODS: An open-label, non-comparative study evaluated an intravenous (i.v.) to oral step-down strategy. Patients with C/IC were treated with i.v. anidulafungin and after 5 days of i.v. therapy had the option to step-down to oral azole therapy (fluconazole or voriconazole) if they met prespecified criteria. The primary endpoint was the global response rate (clinical + microbiological) at end of treatment (EOT) in the modified intent-to-treat (MITT) population (at least one dose of anidulafungin plus positive Candida within 96 hours of study entry). Secondary endpoints included efficacy at other time points and in predefined patient subpopulations. Patients who stepped down early (≤ 7 days' anidulafungin) were identified as the "early switch" subpopulation. RESULTS: In total, 282 patients were enrolled, of whom 250 were included in the MITT population. The MITT global response rate at EOT was 83.7% (95% confidence interval, 78.7-88.8). Global response rates at all time points were generally similar in the early switch subpopulation compared with the MITT population. Global response rates were also similar across multiple Candida species, including C. albicans, C. glabrata, and C. parapsilosis. The most common treatment-related adverse events were nausea and vomiting (four patients each). CONCLUSIONS: A short course of i.v. anidulafungin, followed by early step-down to oral azole therapy, is an effective and well-tolerated approach for the treatment of C/IC. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00496197.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2334-14-97

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • De-escalation to fluconazole was shown to be safe and feasible for multiple Candida species, including C. glabrata.

    “This strategy was shown to be safe and feasible for multiple Candida species, including C. glabrata [94].”

    From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [94]

  • Various PCR formats focusing specifically on the detection of mutations in C. glabrata have been developed.

    “Various PCR formats focussing specifically on the detection of mutations in C. glabrata have been developed (50;51).”

    From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [51]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Vazquez, J., Reboli, A. C., Pappas, P. G., Patterson, T. F., Reinhardt, J., Chin-Hong, P., Tobin, E., Kett, D. H., Biswas, P., & Swanson, R.
Affiliations
  • Cooper Medical School of Rowan University (US)
  • University of Alabama at Birmingham (US)
  • South Texas Veterans Health Care System (US)
  • University of California, San Francisco (US)
  • Albany Medical Center Hospital (US)
  • University of Miami (US)
  • Pfizer (United States) (US)
Corresponding author
Swanson, Robert
Venue
BMC Infectious Diseases
Published
2014-02-21
Volume
14
Issue
1
Pages
97-97
ISSN
1471-2334 (ISSN-L)
OpenAlex
W2043992568
Cited by
101
References
22
Citations by year
2026: 9 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 3 · 2021: 10 · 2020: 10 · 2019: 10 · 2018: 8 · 2017: 10 · 2016: 10 · 2015: 9 · 2014: 4
FWCI
7.73
Type
journal article
Language
en
Open access
Locations
  • BMC Infectious Diseases (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords
candidemia, invasive candidiasis, anidulafungin, step-down therapy, fluconazole, voriconazole, antifungal therapy, Candida albicans, Candida glabrata, Candida parapsilosis, treatment-related adverse events
MeSH terms
Anidulafungin, Administration, Oral, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Candidiasis, Female, Humans, Male, Middle Aged, Research Design, Risk, United States, Fluconazole, Treatment Outcome, Echinocandins, Young Adult, Republic of Korea, Candidiasis, Invasive, Candidemia, Administration, Intravenous, Voriconazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review